

Susanne Spittel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2141686/publications.pdf>

Version: 2024-02-01

14
papers

308
citations

1040056

9
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

303
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. <i>JAMA Neurology</i> , 2022, 79, 121.	9.0	78
2	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
3	Noninvasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: Utilization and survival rates in a cohort study over 12 years in Germany. <i>European Journal of Neurology</i> , 2021, 28, 1160-1171.	3.3	25
4	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. <i>European Journal of Neurology</i> , 2021, 28, 2582-2595.	3.3	16
5	Acceptance of Enhanced Robotic Assistance Systems in People With Amyotrophic Lateral Sclerosis—Associated Motor Impairment: Observational Online Study. <i>JMIR Rehabilitation and Assistive Technologies</i> , 2021, 8, e18972.	2.2	7
6	Dementia Awareness Challenges in Sub-Saharan Africa: A Cross-Sectional Survey Conducted Among School Students in Ghana. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2021, 36, 153331752110553.	1.9	5
7	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 783-785.	1.9	15
8	Awareness challenges of mental health disorder and dementia facing stigmatisation and discrimination: a systematic literature review from Sub-Sahara Africa. <i>Journal of Global Health</i> , 2019, 9, 020419.	2.7	28
9	Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD). <i>BMC Neurology</i> , 2019, 19, 222.	1.8	34
10	Experiences with assistive technologies and devices (ATD) in patients with amyotrophic lateral sclerosis (ALS) and their caregivers. <i>Technology and Disability</i> , 2019, 31, 203-215.	0.6	6
11	Expectations and Concerns Emerging from Experiences with Assistive Technology for ALS Patients. <i>Lecture Notes in Computer Science</i> , 2019, , 57-68.	1.3	1
12	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 342-350.	1.7	33
13	Patient-Reported Outcome of Physical Therapy in Amyotrophic Lateral Sclerosis: Observational Online Study. <i>JMIR Rehabilitation and Assistive Technologies</i> , 2018, 5, e10099.	2.2	26
14	Clinical characteristics and course of dying in patients with amyotrophic lateral sclerosis withdrawing from long-term ventilation. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 53-59.	1.7	26